Skip to main content
. 2010 Oct 27;85(1):410–421. doi: 10.1128/JVI.01826-10

FIG. 2.

FIG. 2.

Anti-ED3 antibodies are completely cross-reactive in secondary dengue infections in humans. (a) Anti-ED3 endpoint titers (EPTs) were determined for all 4 serotypes by direct ELISA against bacterially expressed recombinant ED3. A representative selection of plasma samples, taken 15 to 30 days after defervescence from individuals with secondary dengue infections, is shown (n = 17 out of 76 analyzed). The cutoff levels of seropositivity for each assay are indicated in the symbol key. Assay values below these cutoffs are not depicted, meaning that for some individuals not all 4 titers are shown. Seventeen plasma samples from individuals with secondary infections (S1 to S17) are shown. The current infecting serotype (D1 to D4), as determined by PCR is shown. (b) Competition ELISA for an individual with secondary Den1 infection. The responses against all 4 ED3 serotypes are shown. (c) Competition assay for an individual with secondary Den2 infection. The responses against all 4 ED3 serotypes are shown.